A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

This study will examine the safety and anticancer activity of enfortumab vedotin (EV) given intravenously as monotherapy and in combination with other anticancer therapies as first line (1L) and second line (2L) treatment for patients with urothelial cancer. The primary goal of the study is to determine the safety, tolerability, and efficacy of enfortumab vedotin alone and in combination with pembrolizumab and/or chemotherapy. The study will be conducted in multiple parts: Locally advanced or metastatic urothelial cancer: * Dose escalation * Expansion * Part 1: Cohorts A and Optional B * Part 2: Cohorts D, E, and Optional F * Part 3: Cohort G. * Randomized Cohort K * EV Monotherapy Arm * EV Combination Arm Muscle invasive bladder cancer: * Cohort H * Optional Cohort J * Cohort L